180 related articles for article (PubMed ID: 9624468)
1. Phenotypic study of resistance of beta-lactamase-inhibitor-resistant TEM enzymes which differ by naturally occurring variations and by site-directed substitution at Asp276.
Caniça MM; Caroff N; Barthélémy M; Labia R; Krishnamoorthy R; Paul G; Dupret JM
Antimicrob Agents Chemother; 1998 Jun; 42(6):1323-8. PubMed ID: 9624468
[TBL] [Abstract][Full Text] [Related]
2. X-ray structure of the Asn276Asp variant of the Escherichia coli TEM-1 beta-lactamase: direct observation of electrostatic modulation in resistance to inactivation by clavulanic acid.
Swarén P; Golemi D; Cabantous S; Bulychev A; Maveyraud L; Mobashery S; Samama JP
Biochemistry; 1999 Jul; 38(30):9570-6. PubMed ID: 10423234
[TBL] [Abstract][Full Text] [Related]
3. Aspartic acid for asparagine substitution at position 276 reduces susceptibility to mechanism-based inhibitors in SHV-1 and SHV-5 beta-lactamases.
Giakkoupi P; Tzelepi E; Legakis NJ; Tzouvelekis LS
J Antimicrob Chemother; 1999 Jan; 43(1):23-9. PubMed ID: 10381097
[TBL] [Abstract][Full Text] [Related]
4. Selection and characterization of beta-lactam-beta-lactamase inactivator-resistant mutants following PCR mutagenesis of the TEM-1 beta-lactamase gene.
Vakulenko SB; Geryk B; Kotra LP; Mobashery S; Lerner SA
Antimicrob Agents Chemother; 1998 Jul; 42(7):1542-8. PubMed ID: 9660980
[TBL] [Abstract][Full Text] [Related]
5. Construction and characterization of mutants of the TEM-1 beta-lactamase containing amino acid substitutions associated with both extended-spectrum resistance and resistance to beta-lactamase inhibitors.
Stapleton PD; Shannon KP; French GL
Antimicrob Agents Chemother; 1999 Aug; 43(8):1881-7. PubMed ID: 10428907
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a new TEM-type beta-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli.
Blazquez J; Baquero MR; Canton R; Alos I; Baquero F
Antimicrob Agents Chemother; 1993 Oct; 37(10):2059-63. PubMed ID: 8257123
[TBL] [Abstract][Full Text] [Related]
7. TEM-80, a novel inhibitor-resistant beta-lactamase in a clinical isolate of Enterobacter cloacae.
Arpin C; Labia R; Dubois V; Noury P; Souquet M; Quentin C
Antimicrob Agents Chemother; 2002 May; 46(5):1183-9. PubMed ID: 11959543
[TBL] [Abstract][Full Text] [Related]
8. Selection of variants of the TEM-1 beta-lactamase, encoded by a plasmid of clinical origin, with increased resistance to beta-lactamase inhibitors.
Thomson CJ; Amyes SG
J Antimicrob Chemother; 1993 May; 31(5):655-64. PubMed ID: 8392995
[TBL] [Abstract][Full Text] [Related]
9. Understanding resistance to beta-lactams and beta-lactamase inhibitors in the SHV beta-lactamase: lessons from the mutagenesis of SER-130.
Helfand MS; Bethel CR; Hujer AM; Hujer KM; Anderson VE; Bonomo RA
J Biol Chem; 2003 Dec; 278(52):52724-9. PubMed ID: 14534312
[TBL] [Abstract][Full Text] [Related]
10. The role of a second-shell residue in modifying substrate and inhibitor interactions in the SHV beta-lactamase: a study of ambler position Asn276.
Drawz SM; Bethel CR; Hujer KM; Hurless KN; Distler AM; Caselli E; Prati F; Bonomo RA
Biochemistry; 2009 Jun; 48(21):4557-66. PubMed ID: 19351161
[TBL] [Abstract][Full Text] [Related]
11. Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases.
Bonomo RA; Rudin SA; Shlaes DM
FEMS Microbiol Lett; 1997 Mar; 148(1):59-62. PubMed ID: 9066111
[TBL] [Abstract][Full Text] [Related]
12. Class A beta-lactamases--enzyme-inhibitor interactions and resistance.
Yang Y; Rasmussen BA; Shlaes DM
Pharmacol Ther; 1999 Aug; 83(2):141-51. PubMed ID: 10511459
[TBL] [Abstract][Full Text] [Related]
13. Clinical inhibitor-resistant mutants of the beta-lactamase TEM-1 at amino-acid position 69. Kinetic analysis and molecular modelling.
Chaibi EB; Péduzzi J; Farzaneh S; Barthélémy M; Sirot D; Labia R
Biochim Biophys Acta; 1998 Jan; 1382(1):38-46. PubMed ID: 9507060
[TBL] [Abstract][Full Text] [Related]
14. Characterization and amino acid sequence of IRT-4, a novel TEM-type enzyme with a decreased susceptibility to beta-lactamase inhibitors.
Brun T; Péduzzi J; Caniça MM; Paul G; Névot P; Barthélémy M; Labia R
FEMS Microbiol Lett; 1994 Jul; 120(1-2):111-7. PubMed ID: 8056282
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of nine different types of mutants among 107 inhibitor-resistant TEM beta-lactamases from clinical isolates of Escherichia coli.
Henquell C; Chanal C; Sirot D; Labia R; Sirot J
Antimicrob Agents Chemother; 1995 Feb; 39(2):427-30. PubMed ID: 7726509
[TBL] [Abstract][Full Text] [Related]
16. Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa.
Barnes MD; Taracila MA; Rutter JD; Bethel CR; Galdadas I; Hujer AM; Caselli E; Prati F; Dekker JP; Papp-Wallace KM; Haider S; Bonomo RA
mBio; 2018 Dec; 9(6):. PubMed ID: 30538183
[No Abstract] [Full Text] [Related]
17. Properties of IRT-14 (TEM-45), a newly characterized mutant of TEM-type beta-lactamases.
Caniça MM; Barthélémy M; Gilly L; Labia R; Krishnamoorthy R; Paul G
Antimicrob Agents Chemother; 1997 Feb; 41(2):374-8. PubMed ID: 9021194
[TBL] [Abstract][Full Text] [Related]
18. Inhibitor-resistant TEM beta-lactamases: phenotypic, genetic and biochemical characteristics.
Chaïbi EB; Sirot D; Paul G; Labia R
J Antimicrob Chemother; 1999 Apr; 43(4):447-58. PubMed ID: 10350372
[TBL] [Abstract][Full Text] [Related]
19. Cloning and sequencing of the gene encoding Toho-2, a class A beta-lactamase preferentially inhibited by tazobactam.
Ma L; Ishii Y; Ishiguro M; Matsuzawa H; Yamaguchi K
Antimicrob Agents Chemother; 1998 May; 42(5):1181-6. PubMed ID: 9593147
[TBL] [Abstract][Full Text] [Related]
20. Substitution of Met-69 by Ala or Gly in TEM-1 beta-lactamase confer an increased susceptibility to clavulanic acid and other inhibitors.
Madec S; Blin C; Krishnamoorthy R; Picard B; Chaibi el B; Fouchereau-Péron M; Labia R
FEMS Microbiol Lett; 2002 May; 211(1):13-6. PubMed ID: 12052544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
